Evolving role of adiponectin in cancer-controversies and update

Cancer Biology and Medicine

Volumn 13, Issue 1, 2016, Pages 101-119

  Katira, Arnav ^a   Tan, Peng H ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Adiponectin; Cancer; Therapeutic target

Indexed keywords

ADIPONECTIN; CADHERIN; G PROTEIN COUPLED RECEPTOR; TROGLITAZONE; TUMOR NECROSIS FACTOR;

BREAST CANCER; BROWN ADIPOSE TISSUE; CANCER PROGNOSIS; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENETIC POLYMORPHISM; HEMATOLOGIC DISEASE; HUMAN; HYPOADIPONECTINEMIA; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; NEOPLASM; OBESITY; PANCREAS CANCER; PATHOGENESIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; WHITE ADIPOSE TISSUE;

EID: 84969262165     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.28092/j.issn.2095-3941.2015.0092     Document Type: Review

References (191)

1. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011; 11: 886-95.
2. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J. 2009; 73: 608-14.
3. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6.
4. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7: 947-53.
5. Fujimoto N, Matsuo N, Sumiyoshi H, Yamaguchi K, Saikawa T, Yoshimatsu H, et al. Adiponectin is expressed in the brown adipose tissue and surrounding immature tissues in mouse embryos. Biochim Biophys Acta. 2005; 1731: 1-12.
6. Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology. 2004; 145: 5589-97.
7. Piñeiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005; 579: 5163-9.
8. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005; 54: 117-21.
9. Yokota T, Meka CS, Medina KL, Igarashi H, Comp PC, Takahashi M, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002; 109: 1303-10.
10. Kusminski CM, Mcternan PG, Schraw T, Kos K, O'hare JP, Ahima R, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia. 2007; 50: 634-42.
11. Ayyildiz T, Dolar E, Ugras N, Adim SB, Yerci O. Association of adiponectin receptor (Adipo-R1/-R2) expression and colorectal cancer. Asian Pac J Cancer Prev. 2014; 15: 9385-90.
12. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem. 1996; 271: 10697-703.
13. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A. 2004; 101: 10302-7.
14. Rossi A, Lord J. Adiponectin inhibits neutrophil phagocytosis of Escherichia coli by inhibition of PKB and ERK 1/2 MAPK signalling and Mac-1 activation. PLoS One. 2013; 8: e69108.
15. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007; 117: 375-86.
16. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-9.
17. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemiareperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005; 11: 1096-103.
18. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332-9.
19. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, Ranscht B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 2008; 68: 1407-16.
20. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine. 2010; 37: 11-32.
21. Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, et al. Crystal structures of the human adiponectin receptors. Nature. 2015; 520: 312-6.
22. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26: 439-51.
23. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring). 2006; 14: 28-35.
24. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. Tcadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004; 101: 10308-13.
25. Collins SC, Luan J, Thompson AJ, Daly A, Semple RK, O'rahilly S, et al. Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia. 2007; 50: 555-62.
26. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464: 1313-9.
27. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-95.
28. Tan PH, Tyrrell HE, Gao L, Xu D, Quan J, Gill D, et al. Adiponectin receptor signaling on dendritic cells blunts antitumor immunity. Cancer Res. 2014; 74: 5711-22.
29. Chang LF, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410: 37-40.
30. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428: 332-7.
31. Wu Y, Song P, Zhang W, Liu J, Dai X, Liu Z, et al. Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat Med. 2015; 21: 373-82.
32. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004; 10: 1384-9.
33. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011; 17: 55-63.
34. Karim RZ, Tse GM, Putti TC, Scolyer RA, Lee CS. The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004; 36: 120-8.
35. Svensson R, Shaw RJ. Cancer metabolism: Tumour friend or foe. Nature. 2012; 485: 590-1.
36. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006; 441: 437-43.
37. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441: 424-30.
38. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, et al. Structure of mammalian AMPK and its regulation by ADP. Nature. 2011; 472: 230-3.
39. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013; 493: 346-55.
40. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, Mcmahon LM, et al. mTOR inhibition reverses akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10: 594-601.
41. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14: 1351-6.
42. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006; 574: 63-71.
43. Yano S, Tokumitsu H, Soderling TR. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature. 1998; 396: 584-7.
44. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1996; 378: 785-9.
45. Gurumurthy S, Xie SZ, Alagesan B, Kim J, Yusuf RZ, Saez B, et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature. 2010; 468: U75-659.
46. Habeeb BS, Kitayama J, Nagawa H. Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci. 2011; 102: 999-1006.
47. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, et al. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One. 2009; 4: e4968.
48. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008; 454: 776-9.
49. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature. 2010; 468: 701-4.
50. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med. 2010; 16: 665-70.
51. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010; 139: 1762-73, 1773. e1-5.
52. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004; 101: 2476-81.
53. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007; 92: 1041-8.
54. Nigro E, Scudiero O, Sarnataro D, Mazzarella G, Sofia M, Bianco A, et al. Adiponectin affects lung epithelial A549 cell viability counteracting TNFα and IL-1? toxicity through AdipoR1. Int J Biochem Cell Biol. 2013; 45: 1145-53.
55. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer. 2007; 14: 713-20.
56. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006; 345: 271-9.
57. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9: 798-809.
58. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14: 736-46.
59. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun. 2005; 333: 79-87.
60. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010; 52: 1713-22.
61. Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, et al. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis. 2008; 29: 2195-202.
62. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/betacatenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006; 66: 11462-70.
63. Nepal S, Shrestha A, Park PH. Ubiquitin specific protease 2 acts as a key modulator for the regulation of cell cycle by adiponectin and leptin in cancer cells. Mol Cell Endocrinol. 2015; 412: 44-55.
64. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell. 2009; 36: 469-76.
65. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006; 66: 8625-32.
66. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007; 26: 976-86.
67. Shrestha A, Nepal S, Kim MJ, Chang JH, Kim SH, Jeong GS, et al. Critical role of AMPK/FoxO3A axis in globular Adiponectin- Induced cell cycle arrest and apoptosis in cancer cells. J Cell Physiol. 2016;231:357-69.
68. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998; 396: 177-80.
69. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012; 106: 181-7.
70. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Damianos A, et al. Serial plasma concentrations of adiponectin, leptin, and resistin during therapy in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010; 32: e8-13.
71. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003; 9: 5699-704.
72. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014; 23: 158-65.
73. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004; 89: 1102-7.
74. Gaudet MM, Falk RT, Gierach GL, Lacey JV, Graubard BI, Dorgan JF, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol. 2010; 34: 580-6.
75. Guo MM, Duan XN, Cui SD, Tian FG, Cao XC, Geng CZ, et al. Circulating High-Molecular-Weight (HMW) adiponectin level is related with breast cancer risk better than total adiponectin: a Case-Control study. PLoS One. 2015; 10: e0129246.
76. Akyol M, Demir L, Alacacioglu A, Ellidokuz H, Kucukzeybek Y, Yildiz Y, et al. The effects of adjuvant endocrine treatment on serum leptin, serum adiponectin and body composition in patients with breast cancer: the izmir oncology group (IZOG) study. Chemotherapy. 2015; 61: 57-64.
77. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008; 68: 3178-84.
78. Kaklamani VG, Hoffmann TJ, Thornton TA, Hayes G, Chlebowski R, Van Horn L, et al. Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. Breast Cancer Res Treat. 2013; 139: 461-8.
79. Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2553-7.
80. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011; 12: 234-44.
81. Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and metaanalysis. World J Gastroenterol. 2014; 20: 7941-9.
82. An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a metaanalysis. Eur J Cancer Prev. 2012; 21: 126-33.
83. Joshi RK, Lee SA. Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev. 2014; 15: 397-405.
84. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008; 57: 1531-8.
85. Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer. 2008; 15: 289-99.
86. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005; 11: 3642-6.
87. Ayyildiz T, Dolar E, Ugras N, Eminler AT, Erturk B, Adim SB, et al. Adipo-R1 and adipo-R2 expression in colorectal adenomas and carcinomas. Asian Pac J Cancer Prev. 2015; 16: 367-72.
88. Gialamas SP, Petridou. Tseleni-Balafouta S, spyridopoulos TN, matsoukis IL, Kondi-Pafiti A, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism. 2011; 60: 1530-8.
89. Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013; 62: 561-70.
90. Ou Y, Chen P, Zhou Z, Li C, Liu J, Tajima K, et al. Associations between variants on ADIPOQ and ADIPOR1 with colorectal cancer risk: a Chinese case-control study and updated metaanalysis. BMC Med Genet. 2014; 15: 137.
91. Guo X, Liu J, You L, Li G, Huang Y, Li Y. Association between adiponectin polymorphisms and the risk of colorectal cancer. Genet Test Mol Biomarkers. 2015; 19: 9-13.
92. Ye J, Jiang L, Wu C, Liu A, Mao S, Ge L. Three ADIPOR1 polymorphisms and cancer risk: a Meta-Analysis of Case-Control studies. PLoS One. 2015; 10: e0127253.
93. Zheng Q, Wu H, Cao J. Circulating adiponectin and risk of endometrial cancer. PLoS One. 2015; 10: e0129824.
94. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004; 89: 1160-3.
95. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab. 2007; 92: 255-63.
96. Ma Y, Liu Z, Zhang Y, Lu B. Serum leptin, adiponectin and endometrial cancer risk in Chinese women. J Gynecol Oncol. 2013; 24: 336-41.
97. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. Int J Cancer. 2015; 137: 1967-78.
98. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005; 6: 13-21.
99. Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer. 2013; 20: 151-60.
100. Takemura Y, Osuga Y, Yamauchi T, Kobayashi M, Harada M, Hirata T, et al. Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology. 2006; 147: 3203-10.
101. Ohbuchi Y, Suzuki Y, Hatakeyama I, Nakao Y, Fujito A, Iwasaka T, et al. A lower serum level of middle-molecular-weight adiponectin is a risk factor for endometrial cancer. Int J Clin Oncol. 2014; 19: 667-73.
102. Aminimoghaddam S, Shahrabi-Farahani M, Mohajeri-Tehrani M, Amiri P, Fereidooni F, Larijani B, et al. Epistatic interaction between adiponectin and survivin gene polymorphisms in endometrial carcinoma. Pathol Res Pract. 2015; 211: 293-7.
103. Chen X, Xiang YB, Long JR, Cai H, Cai Q, Cheng J, et al. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer. 2012; 118: 3356-64.
104. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005; 11: 466-72.
105. Seker M, Bilici A, Sonmez B, Ustaalioğlu BB, Gumus M, Gozu H, et al. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol. 2010; 27: 1319-23.
106. Tsukada T, Fushida S, Harada S, Terai S, Yagi Y, Kinoshita J, et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res. 2011; 30: 107.
107. Ayyildiz T, Dolar E, Ugras N, Dizdar OS, Adim SB, Yerci O. Lack of any prognostic relationship between adiponectin receptor (Adipo R1/R2) expression for early/advanced stage gastric cancer. Asian Pac J Cancer Prev. 2014; 15: 4711-6.
108. Wu X, Chen P, Ou Y, Liu J, Li C, Wang H, et al. Association of variants on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients after gastrectomy treatment. Mol Biol Rep. 2015; 42: 355-61.
109. Ye L, Zhang ZY, Du WD, Schneider ME, Qiu Y, Zhou Y, et al. Genetic analysis of ADIPOQ variants and gastric cancer risk: a hospital-based case-control study in China. Med Oncol. 2013; 30: 658.
110. Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol. 2009; 39: 92-6.
111. Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H, et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol. 2010; 136: 261-6.
112. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci. 2008; 53: 597-605.
113. Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014; 5: 534-49.
114. Howard JM, Cathcart MC, Healy L, Beddy P, Muldoon C, Pidgeon GP, et al. Leptin and adiponectin receptor expression in oesophageal cancer. Br J Surg. 2014; 101: 643-52.
115. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol. 2008; 168: 1047-55.
116. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013; 105: 95-103.
117. Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007; 35: 16-21.
118. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009; 20: 625-33.
119. Huang B, Cheng X, Wang D, Peng M, Xue Z, Da Y, et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget. 2014; 5: 4732-45.
120. Kuruma S, Egawa N, Kurata M, Honda G, Kamisawa T, Ueda J, et al. Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan. World J Gastroenterol. 2014; 20: 17456-62.
121. Michikawa T, Inoue M, Sawada N, Sasazuki S, Tanaka Y, Iwasaki M, et al. Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2013; 22: 2250-7.
122. Wang SN, Yang SF, Tsai HH, Lee KT, Yeh YT. Increased adiponectin associated with poor survival in hepatocellular carcinoma. J Gastroenterol. 2014; 49: 1342-51.
123. Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, et al. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology. 2015; 88: 57-68.
124. Shin E, Yu YD, Kim DS, Won NH. Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma. Pathol Oncol Res. 2014; 20: 667-75.
125. Xing SQ, Zhang CG, Yuan JF, Yang HM, Zhao SD, Zhang H. Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol. 2015; 93: 221-31.
126. Cai X, Gan Y, Fan Y, Hu J, Jin Y, Chen F, et al. The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk. Clin Transl Oncol. 2014; 16: 166-72.
127. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS, et al. low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer. 2007; 120: 1573-8.
128. Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol. 2008; 54: 866-73.
129. Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T, Hayakawa M. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2008; 38: 106-11.
130. Liao LM, Schwartz K, Pollak M, Graubard BI, Li Z, Ruterbusch J, et al. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring). 2013; 21: 1478-85.
131. Zhang G, Gu C, Zhu Y, Luo L, Dong D, Wan F, et al. ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma. Cancer Sci. 2015; 106: 687-91.
132. Liao Q, Long C, Deng Z, Bi X, Hu J. The role of circulating adiponectin in prostate cancer: a meta-analysis. Int J Biol Markers. 2015; 30: e22-31.
133. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 308-13.
134. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int. 2009; 82: 203-8.
135. Burton A, Martin RM, Holly J, Lane JA, Donovan JL, Hamdy FC, et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control. 2013; 24: 323-34.
136. Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2014; 23: 890-2.
137. Medina EA, Shi X, Grayson MH, Ankerst DP, Livi CB, Medina MV, et al. The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23: 309-15.
138. Gao Q, Zheng J. Adiponectin-induced antitumor activity on prostatic cancers through inhibiting proliferation. Cell Biochem Biophys. 2014; 70: 461-5.
139. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2618-27.
140. Beebe-Dimmer JL, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis. 2010; 13: 362-8.
141. Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology. 2007; 73: 261-9.
142. Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I, Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 61: 391-7.
143. Petridou ET, Sergentanis TN, Antonopoulos CN, Dessypris N, Matsoukis IL, Aronis K, et al. Insulin resistance: an independent risk factor for lung cancer? Metabolism. 2011; 60: 1100-6.
144. Kerenidi T, Lada M, Tsaroucha A, Georgoulias P, Mystridou P, Gourgoulianis KI. Clinical significance of serum adipokines levels in lung cancer. Med Oncol. 2013; 30: 507.
145. Abdul-Ghafar J, Oh SS, Park SM, Wairagu P, Lee SN, Jeong Y, et al. Expression of adiponectin receptor 1 is indicative of favorable prognosis in non-small cell lung carcinoma. Tohoku J Exp Med. 2013; 229: 153-62.
146. Li Y, Yao Y, Qian X, Shi L, Zhou J, Ma Q, et al. The association of adiponectin gene promoter variations with non-small cell lung cancer in a Han Chinese population. PLoS One. 2015; 10: e0127751.
147. Cui E, Deng A, Wang X, Wang B, Mao W, Feng X, et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochemistry and Cell Biology. 2011; 89: 308-13.
148. Aref S, Ibrahim L, Azmy E, Al Ashary R. Impact of serum adiponectin and leptin levels in acute leukemia. Hematology. 2013; 18: 198-203.
149. Obeid S, Hebbard L. Role of adiponectin and its receptors in cancer. Cancer Biol Med. 2012; 9: 213-20.
150. Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 2011; 118: 5872-82.
151. Avcu F, Ural AU, Yilmaz MI, Bingol N, Nevruz O, Caglar K. Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases. Int J Hematol. 2006; 83: 254-8.
152. Pamuk G, Turgut B, Demir M, Vural O. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res. 2006; 25: 537-41.
153. Mehlen P, Puisieux A. Metastasis:a question of Life or death. Nat Rev Cancer. 2006; 6: 449-58.
154. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009; 28: 2621-33.
155. Saxena NK, Sharma D. Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr. 2010; 4: 358-62.
156. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 2009; 69: 4018-26.
157. Man K, Ng KT, Xu A, Cheng Q, Lo CM, Xiao JW, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res. 2010; 16: 967-77.
158. Wu X, Yan Q, Zhang Z, Du G, Wan X. Acrp30 inhibits leptininduced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep. 2012; 27: 1488-96.
159. Mcmillan DC, Sattar N, Mcardle CS. ABC of obesity. Obesity and cancer. BMJ. 2006; 333: 1109-11.
160. Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Compr Physiol. 2012;2:2775-809.
161. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013; 20: R1-R17.
162. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472-89.
163. Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013; 22: S38-43.
164. Moretti M, Bennett J, Tornatore L, Thotakura AK, Franzoso G. Cancer: NF-κB regulates energy metabolism. Int J Biochem Cell Biol. 2012; 44: 2238-43.
165. Tagami T, Satoh N, Usui T, Yamada K, Shimatsu A, Kuzuya H. Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab. 2004; 89: 1833-7.
166. Otvos L, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011; 11: 90.
167. Otvos L, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, et al. Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. Biopolymers. 2015; 104: 156-66.
168. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short Life in obesity. Nature. 2013; 503: 493-9.
169. Sun Y, Zang Z, Zhong L, Wu M, Su Q, Gao X, et al. Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One. 2013; 8: e63354.
170. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094-9.
171. Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, Yamazaki K, et al. Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. Anticancer Res. 2014; 34: 5133-41.
172. Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, et al. Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New Drugs. 2014; 32: 473-80.
173. Boucher E, Davidenko I, Hadler D, von Roemeling R, Aprile G. PD-0008A randomized, placebo-controlled, phase 2 study of efatutazone maintenance therapy in patients with advanced colorectal cancer who have achieved disease control following first-line chemotherapy. Ann Oncol. 2014; 25(suppl 2): ii8.
174. Williams R. Discontinued in 2013: oncology drugs. Expert Opin Investig Drugs. 2015; 24: 95-110.
175. Tsai JS, Chuang LM, Chen CS, Liang CJ, Chen YL, Chen CY. Troglitazone and Δ2Troglitazone enhance adiponectin expression in monocytes/macrophages through the AMP-activated protein kinase pathway. Mediators Inflamm. 2014; 2014: 726068.
176. Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T, et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci. 2009; 111: 155-66.
177. Hiuge-Shimizu A, Maeda N, Hirata A, Nakatsuji H, Nakamura K, Okuno A, et al. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptorgamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol. 2011; 31: 792-9.
178. Steffan JJ, Dykes SS, Coleman DT, Adams LK, Rogers D, Carroll JL, et al. Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS One. 2014; 9: e87882.
179. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgammaindependent antitumor effects of thiazolidinediones. Cancer Lett. 2009; 276: 119-24.
180. Fu Y. Adiponectin signaling and metabolic syndrome. Prog Mol Biol Transl Sci. 2014; 121: 293-319.
181. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002; 8: 395-9.
182. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003; 79: 391-7.
183. Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide populationbased cohort study. Cerebrovasc Dis. 2013; 36: 145-51.
184. Silva FM, De Almeida JC, Feoli AM. Effect of diet on adiponectin levels in blood. Nutr Rev. 2011; 69: 599-612.
185. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell LV. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care. 2004; 27: 629-30.
186. Yamashita K, Yatsuya H, Muramatsu T, Toyoshima H, Murohara T, Tamakoshi K. Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study. Nutr Diabetes. 2012; 2: e33.
187. Tsukinoki R, Morimoto K, Nakayama K. Association between lifestyle factors and plasma adiponectin levels in Japanese men. Lipids Health Dis. 2005; 4: 27.
188. Fragopoulou E, Panagiotakos DB, Pitsavos C, Tampourlou M, Chrysohoou C, Nomikos T, et al. The association between adherence to the Mediterranean diet and adiponectin levels among healthy adults: the ATTICA study. J Nutr Biochem. 2010; 21: 285-9.
189. Katira A, Tan PH. Adiponectin and its receptor signaling: an anticancer therapeutic target and its implications for anti-tumor immunity. Expert Opin Ther Targets. 2015:1-21.
190. Ealey KN, Kaludjerovic J, Archer MC, Ward WE. Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood). 2008; 233: 1546-53.
191. Holland WL, Scherer PE. Cell biology. Ronning after the adiponectin receptors. Science. 2013; 342: 1460-1.